Enhancing efficacy and reducing toxicity: Therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma
Open Access
- 5 June 2024
- journal article
- review article
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (6) , 101594
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- National Key Research and Development Program of China (2021YFA0909800)
This publication has 127 references indexed in Scilit:
- Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal CarcinomaJAMA, 2023
- Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaJAMA Oncology, 2022
- Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal CarcinomaJAMA, 2022
- Low‐dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinomaCancer Communications, 2022
- Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal CarcinomaJAMA Network Open, 2021
- The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinomaCancer Communications, 2021
- Progress report of a randomized trial comparing long‐term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of ChinaCancer, 2013
- The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinomaCancer, 2009
- Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma detected by magnetic resonance imagingCancer, 2008
- Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiationCancer, 1988